Carroll R G, Riley J L, Levine B L, Blair P J, St Louis D C, June C H
Henry M. Jackson Foundation, Military HIV Research Program, Bethesda, MD, 20889, USA.
Semin Immunol. 1998 Jun;10(3):195-202. doi: 10.1006/smim.1998.0131.
Fusion and entry of the human immunodeficiency virus (HIV) into CD4(+) T lymphocytes requires expression of CD4 and a coreceptor. At least eight chemokine receptors can serve as coreceptors for HIV. Accumulating evidence indicates that multiple factors, including the state of cellular differentia- tion and activation, regulate the expression of alpha- and beta-chemokine receptors on lymphocytes. For example, binding of antibodies to the CD28 coreceptor can downregulate expression of beta-chemokine receptors, and this appears to have important consequences on the susceptibility of CD4(+) T lymphocytes to infection by HIV-1. In contrast, binding of the natural CD28 ligand B7 or antibodies to the CD28 homologue CTLA-4 can upregulate CCR5 expression, sug- gesting a reciprocal interaction between CD28 and CTLA-4 and the regulation of beta-chemokine receptor expression. Thus, the CD28/CTLA-4/B7 co-stimulation pathway is identi- fied as a potential novel target for the control of susceptibility to some strains of HIV-1 infection.
人类免疫缺陷病毒(HIV)融合并进入CD4(+) T淋巴细胞需要CD4和一种共受体的表达。至少有八种趋化因子受体可作为HIV的共受体。越来越多的证据表明,包括细胞分化和激活状态在内的多种因素调节淋巴细胞上α和β趋化因子受体的表达。例如,抗体与CD28共受体结合可下调β趋化因子受体的表达,这似乎对CD4(+) T淋巴细胞感染HIV-1的易感性有重要影响。相反,天然CD28配体B7或抗体与CD28同源物CTLA-4结合可上调CCR5表达,提示CD28和CTLA-4之间存在相互作用以及对β趋化因子受体表达的调节。因此,CD28/CTLA-4/B7共刺激途径被确定为控制对某些HIV-1感染株易感性的潜在新靶点。